Peroxisomal Import of Human Alanine:glyoxylate Aminotransferase Requires Ancillary Targeting Information Remote from Its C Terminus*  

Pia A. J. Huber, Graeme M. Birdsey, Michael J. Lumb, David T. R. Prowse, Tommy J. Perkins, Daniel R. Knight, and Christopher J. Danpure†  

From the Department of Biology, University College London, Gower Street, London WC1E 6BT, United Kingdom

Although human alanine:glyoxylate aminotransferase (AGT) is imported into peroxisomes by a Pex5p-dependent pathway, the properties of its C-terminal tripeptide (KKL) are unlike those of any other type 1 peroxisomal targeting sequence (PTS1). We have previously suggested that AGT might possess ancillary targeting information that enables its unusual PTS1 to work. In this study, we have set out to locate this information and to determine whether or not it is a characteristic of all vertebrate AGTs. Using the two-hybrid system, we show that human AGT interacts with human Pex5p in mammalian cells, but not yeast cells. Using (immuno)fluorescence microscopic analysis of the distribution of various constructs expressed in COS cells, we show the following. 1) The putative ancillary peroxisomal targeting information (PTS1A) in human AGT is located entirely within the smaller C-terminal structural domain of 110 amino acids, with the sequence between Val-324 and Ile-345 being the most likely candidate region. 2) The PTS1A is present in all mammalian AGTs studied (human, rat, guinea pig, rabbit, and cat), but not amphibian AGT (Xenopus). 3) The PTS1A is necessary for peroxisomal import of human, rabbit, and cat AGTs, but not rat and guinea pig AGTs. We speculate that the internal PTS1A of human AGT works in concert with the C-terminal PTS1 by interacting with Pex5p indirectly with the aid of a yet-to-be-identified mammal-specific adapter molecule. This interaction might reshape the tricopeptide repeat domain allosterically, enabling it to accept KKL as a functional PTS1.

Alanine:glyoxylate aminotransferase (AGT), EC 2.6.1.44 catalyzes the transamination of the intermediary metabolite glyoxylate to glycine. A deficiency of AGT, as occurs in the hereditary disease primary hyperoxaluria type 1, allows glyoxylate to be oxidized to oxalate instead. The resulting increased synthesis and excretion of oxalate leads to the deposition of insoluble calcium oxalate in the kidney and urinary tract and, ultimately, renal failure (1). AGT is normally peroxisomal in human liver, but in a subset of primary hyperoxaluria type 1 patients it is mistargeted to mitochondria (2). Although the molecular basis of the peroxisome-to-mitochondrion mistargeting of AGT in primary hyperoxaluria type 1 has been subject to extensive investigation (3–6), its normal targeting to peroxisomes has received much less attention (7, 8).

Peroxisomal import of human AGT is dependent on the presence of the type 1 peroxisomal targeting sequence (PTS1) receptor Pex5p, but not the PTS2 receptor Pex7p (7). However, several features of the peroxisomal targeting of AGT are unusual when compared with the targeting of other peroxisomal proteins. The C-terminal tripeptide of human AGT is KKL (9), which has a two-out-of-three match with the prototypical consensus PTS1 of (S/A/C)/K/R/H/L/M (10, 11). KKL is necessary for peroxisomal targeting of human AGT but insufficient to direct the peroxisomal targeting of reporter proteins, such as bacterial chloramphenicol acetyltransferase or firefly luciferase (7, 12). This has led to the suggestion that additional targeting information may be necessary beyond that provided by the C-terminal tripeptide (7).

PTS1s are recognized by, and interact with, the tricopeptide repeat (TPR) domain located in the C-terminal part of Pex5p (13, 14). Crystallographic analysis of human Pex5p bound to a synthetic hexapeptide ending in SKL showed that a small uncharged residue is required in the −3 position (15). Lysine, which is the residue at −3 in human AGT, does not fit this description, being large and positively charged. Therefore, it is not surprising that human AGT does not appear to interact directly with human Pex5p in the yeast two-hybrid assay (8). However, what is surprising is that the peroxisomal import of human AGT is still Pex5p-dependent (7). Although numerous tripeptides have been shown to be able to act as PTS1s, albeit in a highly context-dependent fashion, KKL has never been shown to either act as a PTS1 or interact directly with Pex5p (for example, see Refs. 16–19). In addition, to our knowledge, KKL has not yet been found at the C terminus of any other peroxisomal protein.

Further evidence that the human AGT PTS1 behaves very differently from other PTS1 sequences is shown by the observation that normal human AGT (ending in KKL) does not compete with other PTS1 proteins for peroxisomal import in a transient overexpression system, whereas mutated human AGT (ending in SKL) and GFP-SKL do (8). In addition, the peroxisomal import of
AGT is conserved in rat, mouse, guinea pig, human, and koala, and baboon, or acyl-CoA oxidase, the C terminus of which (i.e. SKL) is conserved in rat, mouse, pig, and baboon.

For example, AGT is mainly mitochondrial with only a small proportion of hepatocytes, AGT is peroxisomal. However, in the cat and dog, AGT is mainly mitochondrial with only a small proportion of hepatocytes, AGT is peroxisomal. Moreover, it is KKL in human (9) and marmoset (20), HRL in guinea pig (21), SQL in rabbit (20), and KL in cow (EMBL accession number AAT2010679/1), and SKL in cow (EMBL accession number AV605720, Bos taurus cDNA). This evolutionary variability differs from archetypal PTS1 proteins, such as urate oxidase, the C terminus of which (i.e. SKL) is conserved in rat, mouse, pig, and baboon.

A complicating factor with AGT, but as far as we are aware no other peroxisomal protein, is that its intracellular compartmentalization varies between different mammalian species (25–30). For example, in the human, rabbit, and guinea pig hepatocytes, AGT is peroxisomal. However, in other mammals, such as marmoset and rat, AGT is mainly mitochondrial with only a small proportion of hepatocytes. In other mammalian species from which AGT is derived, AGT is mitochondrial and cytosolic. Interestingly, the C terminus of Xenopus AGT (i.e. KKM), although very similar to the KKL of human AGT, appears to be unable to act as a PTS1 (28).

Since the original discovery of the PTS1, it has become increasingly clear that a wide variety of tripeptides can target proteins to peroxisomes, albeit in a context-dependent manner. Context can be provided by the type of cell (particularly the species from which it is derived) or the nature of the cargo (i.e. the protein to be imported). In the case of the former, Pex5p from different species might have different PTS1 requirements (16, 31). Whereas in the case of the latter, amino acids in close proximity (i.e. within 10–20 residues) to the C-terminal tripeptide can markedly influence the properties of, and allowable residues within, the PTS1 (16, 17, 32–35). The importance of specific residues near the C terminus appears to be particularly important if the C-terminal tripeptide deviates from the conservative consensus PTS1 (16). However, even the canonical PTS1 SKL can be inhibited by the close proximity of acidic amino acids (12). Human AGT is unusual in that the degeneracy of its PTS1 occurs in the same protein and cellular context. Human AGT can be targeted to peroxisomes not only by KKL, but also by all the other tripeptides found in mammalian AGTs (i.e. NKL, SQL, HRL, and SKL) as well as the glycosomal targeting sequence SSL (7). However, there are limits to the degeneracy of the allowable PTS1s in human AGT; SEL, DEL, LLL, and the Xenopus C terminus, KKM, do not work (7, 28).

Although amino acids within the last 40 or so residues of human AGT were shown to be necessary for its peroxisomal targeting, they were still not sufficient for the peroxisomal targeting of reporter proteins (7, 12). This suggests that any additional peroxisomal targeting information in human AGT must extend beyond the C-terminal 40 amino acids. Surprisingly, this extra information is evidently absent from Xenopus AGT, despite being 66% identical (and 75% similar) to human AGT. This was shown by the observation that, although cytosolic Xenopus AGT could be redirected to the peroxisomes if its C-terminal KKM was replaced by SKL, it could not if it was replaced by KKL (28).

Although the crystal structure of the TPR domain of human Pex5p has been solved (15), the structures of very few of its cargo proteins have been determined. Therefore, it is not clear to what extent parts of the cargo, other than the C-terminal tripeptide, might interact with the import receptor and affect its function, particularly the acceptability of different C-terminal tripeptides as PTS1s. We have recently solved the crystal structure of human AGT to 2.5 Å and shown it to exist as an intimate dimer composed of two identical subunits, each of which can be divided into an N-terminal extension of about 20 amino acids, a large domain of about 260 amino acids containing most of the active site and the dimerization interface, and a smaller C-terminal domain of about 110 amino acids of uncertain function (36) (Fig. 1). The structures of AGTs from other species are likely to be very similar to that of human AGT, thereby allowing the properties of their PTS1s to be analyzed in terms of the overall protein structure, rather than just in terms of polypeptide sequence.

In the present study, we have attempted to localize the putative ancillary peroxisomal targeting information in human AGT by expression of a wide variety of AGT-GFP and interspecies AGT constructs in COS cells and determining their distribution by confocal (immuno)fluorescence microscopy. In addition, we have re-analyzed the interaction between human AGT and human Pex5p, using the mammalian two-hybrid system.

**MATERIALS AND METHODS**

**Expression Constructs**—The oligonucleotide primers used in the present study were synthesized by MWG Biotech (Germany) and are described in the Supplementary Materials. The expression constructs, cloned into either pcDNA3 (Invitrogen) or pEGFP (BD Biosciences), are described in Table I.

**GFP-oligopeptide Constructs**—The GFP constructs encoding C-terminal AGT-oligopeptide hexapeptides were made using PCR with primers that annealed to the 5′ and 3′ ends of the GFP coding sequence. The 3′ primers additionally contained coding sequence for the desired C-terminal AGT hexapeptide (see Supplementary Materials). pEGFP.N3 (BD Biosciences) was used as template for PCR amplification of GFP for all AGT-oligopeptide constructs, except GFP-PKKKL for which the template was GFP-SKL (8). Reverse primers used were P23 for GFP-CPKKKL, P24 for GFP-CPRHRL, P25 for GFP-PKKSL, P26 for GFP-CAQSQL, P27 for GFP-PKKKL, and P38 for GFP-CSNKKL. Each of these reverse primers was paired with the forward primer P22, which anneals upstream of the multiple cloning site in pEGFP.N3 or in the construct GFP-SKL. The resulting PCR products were digested with XbaI at the restriction site that was introduced by the reverse primers, and BamHI at the restriction site in the multiple cloning site downstream of the P22 primer. The resulting DNA sequence fragments were ligated into BamHI-XbaI-digested pcDNA3.

**GFP-AGT Constructs**—GFP-HsAGT-KKL was made by first producing an intermediate construct pcDNA3.GFP-CPRHRL. The region coding for SKL in GFP-SKL was replaced by an XhoI restriction site by PCR amplification using primers P34 and P35. The PCR product was then subcloned into pcDNA3 using the restriction sites KpnI at the 5′ end and XbaI at the 3′ end (outside the newly constructed XhoI site in the insert) to give pcDNA3.GFP. Human AGT was amplified from the template pAGT (HsAGT-KKL in Bluescript KS+) (8) using the primers P36 and P37. The PCR product was cut with XhoI and XbaI and cloned into XhoI-XbaI-digested pcDNA3.GFP to give GFP-HsAGT-KKL.

To make GFP-HsAGT346–392-KKL, the appropriate region of AGT was amplified by PCR from pAGT using primers P19 and P20. The PCR product was digested with XhoI and XbaI and cloned into the intermediate construct pcDNA3. GFP-HsAGT361–392-KKL was also made from pAGT using primers P20 and P21. The PCR product was digested with BamHI and XhoI and cloned into the intermediate construct pcDNA3.GFP. To make GFP-HsAGT361–392-KKL, the appropriate region of AGT was amplified by PCR from HsAGT-KKL (8), using the primers P11 and P18. The PCR product was cut with XhoI and BstEII and cloned into XhoI-BstEII-digested pcDNA3.GFP to give GFP-HsAGT-KKL.

**Mammalian AGT-KKL Constructs**—The rat, guinea pig, rabbit, and cat AGT-KKL and the cat AGT-CPRHRL constructs were made using the appropriate species-specific cDNAs as templates for PCR, and primers (Supplementary Materials) that introduced restriction sites for cloning and, for the reverse strand primers, changed the species-specific C-terminal tripeptides to KKL and the C-terminal hexapeptide to CPKKKL. Primers P28 and P29 were used to amplify guinea pig AGT-KKL, P30 and P31 were used for rat AGT-KKL, P6 and P7 were used for rabbit AGT-KKL, P32 and P33 were used for cat AGT-KKL, and P32 and P33 were used for cat AGT-KKL.
FIG. 1. Crystal structure of human AGT. A–D, the crystal structure of human AGT (36). A, overall topology of the AGT homodimer. The subunits are arbitrarily designated α (blue) and β (red). PLP (green) indicates the positions of the cofactor pyridoxal phosphate. B, a magnified view of the α subunit showing the large N-terminal structural domain (blue) and the small C-terminal structural domain (brown). C, a magnified view of the small domain indicating the various Xenopus-human AGT and GFP-human AGT fusion protein junctions discussed in the text, the segments being arbitrarily color-coded. The numbers indicate the position of the more C-terminal of the pair of residues at the junctions. The last residue identifiable in the crystal structure is 390; therefore, the C-terminal KKL indicated simply represents the approximate location of the C terminus of AGT. D, the whole AGT homodimer color coded as in A except for the putative ancillary targeting domain Val282–Ile283 which is shown in yellow.

TABLE I
Description of the AGT expression constructs used in the present study

| Construct | Description |
|-----------|-------------|
| HsAGT-KKL | Human (H. sapiens) AGT encoded by the more common major AGXT allele (8); C terminus = KKL |
| HsAGT-SKL | Human AGT in which the C-terminal KKL is replaced by SKL (7) |
| HsAGT-KKM | Human AGT in which the C-terminal KKL is replaced by KKM (28) |
| HsAGT-SKL | Human AGT in which the C-terminal KKL is replaced by SKL (7) |
| XAGT-KKL | XAGT encoded by the short transcript in which the C-terminal KKM is replaced by KKL (28) |
| XAGT-KKM | XAGT encoded by the short transcript in which the C-terminal KKM is replaced by SKL (28) |
| Hs283X-KKL | Residues 1–282 of HaAGT fused to residues 283–389 of XiAGT with a C-terminal KKL |
| Hs283X-SKL | Residues 1–282 of HaAGT fused to residues 283–389 of XiAGT with a C-terminal SKL |
| Xi306Hs-XKKL | Residues 1–306 of XiAGT fused to residues 324–392 of HaAGT |
| Xi324Hs-XKKL | Residues 1–324 of XiAGT fused to residues 324–392 of HaAGT |
| Xi361Hs-XKKL | Residues 1–361 of XiAGT fused to residues 361–392 of HaAGT |
| GFP-HsAGT-KKL | GFP fused to HaAGT |
| GFP-HsAGT | GFP fused to residues 283–392 of HaAGT |
| GFP-HsAGT-KKKL | GFP fused to residues 346–392 of HaAGT |
| GFP-HsAGT | GFP fused to residues 361–392 of HaAGT |
| GFP-PKKKL | GFP fused to residues 388–392 of HaAGT (i.e. C-terminal 5 amino acids of HaAGT) |
| GFP-PKKKL | GFP fused to the pentapeptide PKSKL |
| GFP-PKKKL | GFP fused to the C-terminal 6 amino acids of guinea pig AGT |
| GFP-PKKKL | GFP fused to the C-terminal 6 amino acids of rat/mouse AGT |
| GFP-PKKKL | GFP fused to the C-terminal 6 amino acids of cat AGT |
| GFP-CQSKL | GFP fused to the C-terminal 6 amino acids of rabbit AGT |
| HaAGT-KKL | Rat (R. norvegicus) AGT in which the normal C-terminal tripeptide (NKL) is replaced by KKL |
| HaAGT-KKL | Guinea pig (C. porcellus) AGT in which the normal C-terminal tripeptide (NKL) is replaced by KKL |
| OcAGT-KKL | Rabbit (Oryctolagus cuniculus) AGT in which the normal C-terminal tripeptide (SQL) is replaced by KKL |
| FaAGT-KKL | Cat (F. cattus) AGT in which the normal C-terminal hexapeptide (CSRNLK) is replaced by CPKKKL |

This construct (fused to the GAL4 DNA-binding domain) was also used for the mammalian two-hybrid studies.

These constructs (fused to the GALADNA-binding domain) were used only for the mammalian two-hybrid studies.

A single human AGT subunit contains 392 amino acids, whereas Xenopus AGT contains 391 amino acids. As a result, residues 282 and 283, which are at the junction of the large N-terminal and small C-terminal structural domains of human AGT, are equivalent to residues 281 and 282 in Xenopus AGT.

and P39 were used for cat AGT-CPPKKKL. Guinea pig and rat AGT-KKL were subcloned into BamHI-XhoI-digested pcDNAs. Rabbit AGT-KKL, cat AGT-KKL, and cat AGT-CPPKKKL were subcloned into KpnI-EcoRI-digested pcDNAs.
species-specific non-overlapping primers upstream or downstream of the chimeric junction, and a dual species overlapping primer at the junction. To make Hs283Xl-KKL, primers P1 and P2 were used with template HsAGT-KKL and primers P3 and P4 were used with template XlAGT-KKL (28). For Xl283Hs-KKL, primers P8 and P9 were used with template XlAGT-KKL and primers P10 and P11 were used with template HsAGT-KKL. For Xl306Hs-KKL, primers P8 and P12 were used with template XlAGT-KKL and primers P13 and P11 were used with template HsAGT-KKL. For Xl324Hs-KKL, primers P8 and P14 were used with template XlAGT-KKL and primers P15 and P11 were used with template HsAGT-KKL. For Xl324Hs-KKL, primers P8 and P16 were used with template XlAGT-KKL and primers P17 and P11 were used with template HsAGT-KKL. The two amplified fragments, one human and one Xenopus, were then mixed and subjected to a further 10 PCR cycles without primers to anneal the two fragments at the junctional overlap and extend each to the end. The products of this procedure served as templates for a final PCR round of 10 cycles, with primers P5 and P11 for the various Xl-Hs-KKL chimeras, and P1 and P4 for the single Hs-Xl-KKL chimera. The final PCR products were digested with KpnI and XhoI and cloned into pcDNA3. The construct Hs283Xl-SKL was produced by PCR amplification using primers P1 and P5 with template Hs283Xl-SKL and subcloning into KpnI-XhoI digested pcDNA3. All constructs were checked by DNA sequencing for their sequence (MWG-Biotech). 

Mammalian Two-hybrid Constructs—The positive control vector pm3-VP16, expressing a fusion of the GAL4 DNA-binding domain (BD) to the VP16 activation domain (AD) and the pG5CAT chloramphenicol acetyl transferase reporter vector were purchased from Clontech/BD Biosciences. Normal human AGT and human AGT in which the C-terminal tripeptide KKL was replaced by SKL were amplified by PCR from the E. coli expression vector pVP16 (Clontech/BD Biosciences), which was cut with HindIII, then filled in with Klenow polymerase and then cut with the restriction enzymes EcoRI and XhoI. The PCR products were cut with the restriction enzymes EcoRI and XhoI and then ligated into the vector pGAL4 DNA-binding, which was cut with the same restriction enzymes. Human AGT in which the C-terminal tripeptide KKL was replaced by KKM and human AGT in which the C-terminal three amino acids were deleted were amplified by PCR from the plasmid pVP16-HAGT-KKM (28) using the primers P40 with P41 (HaAGT-KKM) and P40 with P42 (HaAGT-SKL). The PCR products were cut with the restriction enzymes EcoRI and SalI and then ligated into the vector pGAL4 DNA-binding, which was cut with the same restriction enzymes. The mammalian AGT construct was visualized using guinea pig anti-human catalase antisera followed by biotinylated goat anti-guinea pig IgG and Texas Red-avidin DCS (Vector, Peterborough, UK). The fluorescence of fluorescent tagged catalase was visualized using a confocal laser-scanning fluorescence microscope, either the MRC 1024 or the Radiance 2100. 

RESULTS

Human AGT Interacts with Human Pex5p in Mammalian, but Not Yeast, Cells—Previous studies have yielded conflicting results regarding the peroxisomal import pathway taken by human AGT. Although import in transfected mammalian tissue culture cells is dependent on expression of Pex5p, no interaction between AGT and human Pex5p is detectable in the yeast two-hybrid system (see the introduction). To check whether the latter result was an artifact of the heterologous system used, we have repeated the interaction in the present study using a mammalian two-hybrid system. The results in Fig. 2, show clearly that HaAGT-KKL does interact with HsPex5p (both long and short forms) in COS cells. Notwithstanding the qualitative, or at best semi-quantitative, nature of the two-hybrid reaction, it appeared that the strength of the interaction between HaAGT-KKL and HsPex5p was similar to that of HaAGT-SKL. On the other hand, two AGT constructs mutated at the C terminus, HaAGT-KKM (28) and HaAGT-ΔΔ (7), which are normally not to be targeted to peroxisomes, did not interact with either form of Pex5p.

C Termini of Rat/Mouse and Guinea Pig AGTs, but Not Human, Rabbit, or Cat AGTs, Are Sufficient to Direct the Peroxisomal Import of GFP—Previous studies have shown that the human PTS1 KKL is not able to target the reporter proteins chloramphenicol acetyl transferase and firefly luciferase to peroxisomes (7). On the other hand, a 15-mer oligopeptide ending in SQL (the C-terminal tripeptide of rabbit AGT) was able to target GFP to peroxisomes (16). To assess the peroxisomal targeting ability of the different mammalian AGT C termini, various GFP constructs were expressed in COS cells,
and the distribution was determined by fluorescence confocal microscopy. The results showed that, whereas GFP-CPKNKL (rat/mouse), GFP-CPRHRL (guinea pig), and GFP-PKSKL (prototypical PTS1) were targeted to peroxisomes, GFP-PKKKL (human/marmoset), GFP-CAQSQL (rabbit), and GFP-CSRNKL (cat) remained cytosolic (Figs. 3 and 7 (a–f) and Table II). During the course of these experiments, it was noticed that a substantial proportion (~85%) of cells expressing GFP-CSRNKL did not express punctuate catalase. The reason for this is unclear, but in any case GFP in these cells was entirely cytosolic (Fig. 7(A–J)). Overall, these experiments showed that the C-terminal hexapeptides of rat/mouse and guinea pig AGTs were sufficient to target GFP to peroxisomes, those of human/marmoset, rabbit, and cat were not.

**KKL Is Able to Target Human, Rat, Guinea Pig, and Rabbit AGTs, but Not Cat and Xenopus AGTs, to Peroxisomes**—We have proposed previously that human AGT, but not Xenopus AGT, might contain additional peroxisomal targeting information (see above). To test whether this extra information is unique to human AGT or whether it is a common feature of mammalian AGTs, we have examined whether KKL is able to direct the peroxisomal import of other mammalian AGTs by substituting it for the naturally occurring C-terminal tripeptide in rat, guinea pig, rabbit, and cat AGTs. The results showed that KKL could direct the peroxisomal targeting of rat, guinea pig, and rabbit AGTs, as well as human AGT, but it could not do so for cat AGT (Figs. 4 and 7 (g–j) and Table II). The failure of KKL to target cat AGT to peroxisomes appeared to be due to an incompatibility between this tripeptide and the amino acids immediately upstream in cat AGT (i.e. CSR), because the C-terminal hexapeptide of human AGT (i.e. CPKKKL) was able to target the feline protein to peroxisomes (Figs. 4 (I and J) and 7 (l and m)). These results suggest that ancillary peroxisomal targeting information is present in all mammalian AGTs, including that of the cat.

A **Large Extended C-terminal Region of Human AGT Is Required to Direct the Peroxisomal Targeting of GFP**—Numerous studies have shown that the efficiency of the Pex5p-dependent import of peroxisomal proteins can be influenced by the presence of particular residues within 10–20 amino acids of the C terminus (see the introduction). To determine the minimum contiguous sequence necessary to target human AGT to peroxisomes, we have fused full-length and variously truncated C-terminal fragments of human AGT to the C terminus of GFP and determined their subcellular distribution in transfected COS cells. The results showed that full-length human AGT, and its small C-terminal structural domain of 110 amino acids (residues 283–392) were able to target GFP to peroxisomes (Figs. 5 (A–D) and 7 (I and m)). However, GFP fusion constructs containing smaller amounts of AGT C-terminal sequence (i.e. .
residues 346–392 and 361–392) were not (Figs. 5 (E–H) and 7 (n and o)).

**Human-Xenopus AGT Chimeras Suggest That the Putative Additional Peroxisomal Targeting Information in Human AGT Is Located in a Region of the C-terminal Small Structural Domain of AGT Remote from Its C Terminus—**A complicating factor in the GFP fusion experiments above was that several of the constructs showed a tendency to aggregate when expressed in COS cells. Because conformational stability appeared to have been compromised and might have affected targeting secondarily, we sought another system that was likely to maintain AGT structure. *Xenopus* and human AGTs are almost certainly structurally conserved, and we considered that *Xenopus*-human AGT fusion proteins would be much less prone to conformational instability and aggregation than GFP-AGT fusion proteins.

Taking advantage of the likely absence of the ancillary peroxisomal targeting information in *Xenopus* AGT, we constructed a series of human-*Xenopus* chimeric fusion proteins, containing varying amounts of human and *Xenopus* sequence, and determined their subcellular distribution in transfected COS cells. The results confirmed the GFP fusion studies above that showed that the totality of the peroxisomal targeting information of human AGT resides in the small C-terminal structural domain. This was shown by the fact that, whereas the C-terminal pentapeptide PKKKL can direct cat AGT to peroxisomes, because CPK at residues 6 to 4 is compatible with KKL, the distribution in dog is similar to that of the cat. It is likely that internal translation produces the polypeptide that is targeted to peroxisomes, as in the cat.

The ability of the C terminus of cow AGT to target GFP to peroxisomes has not been formally tested. However, in numerous experiments SKL has been shown to be able to target reporter proteins to peroxisomes unless an acidic amino acid is in close proximity.

### Table II

| Species             | C-terminal hexapeptide | Does full-length AGT target to peroxisomes? | Can C-terminal pentapeptide direct the peroxisomal import of GFP fusions? | Does replacement of the natural C-terminal tripeptide by KKL still allow peroxisomal import of full-length AGT? |
|---------------------|------------------------|---------------------------------------------|--------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Human/marmoset      | CPKKKL                 | Yes                                         | No                                                                       | Yes                                                                                               |
| Rat/mouse           | CPKKKL                 | Yes                                         | Yes                                                                      | Yes                                                                                               |
| Guinea pig          | CPKKKL                 | Yes                                         | Yes                                                                      | Yes                                                                                               |
| Rabbit              | CPKKKL                 | Yes                                         | No                                                                       | Yes                                                                                               |
| Cat                 | CPKKKL                 | Yes<sup>a</sup>                             | No                                                                       | No<sup>b</sup>                                                                                     |
| Dog                 | CPKKKL                 | Yes<sup>a</sup>                             | ?                                                                        | ?                                                                                                  |
| Cow                 | CPKKKL                 | <sup>7</sup>                                | ?                                                                        | ?                                                                                                  |
| *Xenopus*           | CPKKKL                 | No                                          | No                                                                       | No                                                                                                 |

<sup>a</sup> The majority of AGT is targeted to the mitochondria in cat hepatocytes due to the presence of an N-terminal MTS. Internal translation leads to a shorter polypeptide missing the MTS, which is targeted to the peroxisomes.

<sup>b</sup> The human C-terminal tripeptide KKL cannot direct cat AGT to peroxisomes, because it is inhibited by residues 6 to 4 (i.e., CSR). However, the human C-terminal pentapeptide PKKKL can direct cat AGT to peroxisomes, because CPK at residues 6 to 4 is compatible with KKL.

<sup>c</sup> The distribution in dog is similar to that of the cat. It is likely that internal translation produces the polypeptide that is targeted to peroxisomes, as in the cat.

<sup>d</sup> The distribution of AGT in the cow is unknown. However, in other artiodactyls it is both mitochondrial and peroxisomal.

<sup>e</sup> The ability of the C terminus of cow AGT to target GFP to peroxisomes has not been formally tested. However, in numerous experiments SKL has been shown to be able to target reporter proteins to peroxisomes unless an acidic amino acid is in close proximity.

### Discussion

**Cell Context Dependence of the Interaction between Human AGT and Human Pex5p**—The fact that human AGT is able to interact with human Pex5p in mammalian cells (this study), but is unable to do so in yeast cells (8), suggests that, unlike for other PTS1 proteins, the correct cellular environment is important for AGT. The most likely explanation for this is that the mammalian cell provides something that the yeast cell does not. From our previous work (8), we suggested that the interaction between AGT and Pex5p might require the presence of an adaptor molecule. One explanation of the present two-hybrid results is that this adaptor is present in mammalian cells, but not yeast cells. The role of this putative adaptor could be to allosterically modify the TPR domain of Pex5p allowing it to accept the degenerate range of C-terminal tripeptides known to be able to direct human AGT to peroxisomes.

**Location of the Ancillary Targeting Information in Human AGT**—The results presented in this report on the intracellular targeting of *XAGT-HsAGT* and GFP-*HsAGT* fusion proteins show not only that all of the information required by human AGT to target it to peroxisomes is contained within the smaller C-terminal domain of 110 amino acids (residues 283–392), but also that the ancillary targeting information (PTS1A) is possibly concentrated in the 22-amino acid region from Val-324 to Ile-345 (see Fig. 1C). Although a number of studies have shown that residues in close proximity to the C-terminal tripeptide (i.e., within 10–20 amino acids) can influence the ability of this tripeptide to function as a PTS1 (see the introduction), we are not aware of any studies that have demonstrated a role for
and normal human AGT); i.e. was distributed diffusely (A–H) (see Table I for a description of the constructs). After 48 h the cells were labeled and then visualized for AGT (see below). Even if the PTS1A is not required, major consequences of perturbation of the spatial relationship between the ancillary targeting region and the C-terminal tripeptide (see below). Even if the PTS1A is not required, major structural alterations to the intervening regions could affect PTS1 functioning. For example, some point mutations predicted to disrupt the C-terminal α-helix (residues 371–387) inhibit the peroxisomal targeting of rat AGT (33), even though we have shown in the present study that its C-terminal hexapeptide CPKKKL does not require any additional targeting information to work as a PTS1. In addition, certain point mutations upstream of the C-terminal tripeptide, especially the close proximity of acidic residues, can interfere with the peroxisomal targeting of human AGT (12), even if the C-terminal KKL is replaced by SKL, probably due to inhibiting the operation of the C-terminal PTS1 rather than due to the loss of any extra targeting information.

Cat AGT is unusual among the mammalian AGTs, because it is the only one in which the residues immediately upstream of the C-terminal tripeptide (i.e. CSR) appear to compromise the ability of KKL to act as a PTS1. In vertebrate AGTs, residues −4 to −6 are much better conserved than the terminal residues −1 to −3. For example, they are CPK in human/marmoset, rat/mouse, and CPR in guinea pig, dog, and cow (see Table II). The least well conserved are the rabbit (CAQ) and the cat (CSR). Although the structural basis of the cat AGT-specific interference of KKL function remains unknown, it is clearly related to the presence of serine at −5. It appears that, although closely positioned residues can prevent KKL from working as a PTS1, they cannot allow KKL to work if the PTS1A is not present. This is clearly shown by Xenopus AGT, the C terminus of which is almost identical to that of human AGT (CPKKKM versus CPKKKL, see Table II). Despite this, it cannot be directed to peroxisomes by replacing the final methionine by leucine.

The ability of KKL (or CPKKKL in the case of the cat), to
target all the mammalian AGTs to peroxisomes suggests that all these mammalian AGTs possess the PTS1A, even though the GFP fusion protein results indicate that it is not required in the rodents (i.e. rat, mouse, and guinea pig). In Xenopus AGT, which does not contain a PTS1A, the region between residues 324 and 345 is much more poorly conserved compared with the same region in human AGT than is the whole protein (36% identical compared with 66%). However, this region in rat, guinea pig, rabbit, and cat AGTs is as well conserved, compared with human AGT, as is the rest of the protein (77 to 91% identical compared with 78 to 83%). This level of conservation, or lack of conservation, of this region is compatible with its ability to function as a PTS1A in mammalian AGT, but not Xenopus AGT.

Possible Mechanism of Action of the Ancillary Peroxisomal Targeting Information (PTS1A)—The region between Val-324 and Ile-345, which our present results suggest is the most likely candidate for the PTS1A, is exposed on the surface of the AGT dimer. Although it is 47 to 68 residues upstream of the C terminus, in the three-dimensional crystal structure of AGT the PTS1A and the PTS1 are very close (see Fig. 1D). For example, the main chain of Gly-329 is only 4.5 Å from that of Lys-389. If close proximity between residues 324 to 345 (the PTS1A) and residues 390 to 392 (the PTS1) is important, then it is not surprising that deletions or point mutations in the intervening regions that disrupt their spatial relationship should also interfere with peroxisomal targeting.

In the absence of explicit data on the crystal structure of the AGT-Pex5p import complex, the exact mechanism of action of the PTS1A remains speculative. The crystal structure of the TPR domain of human Pex5p with a hexapeptide ending in SKL explains the requirement of this tripeptide, or conservative variants thereof, in the peroxisomal targeting of most peroxisomal proteins (15). However, it fails to explain how mammalian AGTs, uniquely, can be targeted to peroxisomes by KKL, SQL, NKI, HRL, SKL, SSL, and probably many other tripeptides. One possible role for the ancillary targeting information is to bind directly or indirectly to human Pex5p causing an allosteric change to the conformation of the TPR region to allow it to accept such a degenerate range of PTS1s. Our previous (8) and present studies indicate that the peroxisomal import of human AGT might require an additional factor that is present in mammalian, but not yeast, cells. Therefore, it is possible that the PTS1A in human AGT interacts with this putative additional factor, rather than human Pex5p directly. The human AGT-adaptor complex would in turn interact with human Pex5p altering the specificity of its TPR domain.

Evolutionary Origins of the PTS1A in Mammalian AGT—If our interpretation of the data presented in this and previous papers is correct, then the question remains as to why human AGT has evolved such a mechanism for peroxisomal import, whereas most other peroxisomal proteins seem able to rely on the necessity and sufficiency of the prototypical PTS1 C-terminal tripeptide. The answer probably lies in the unique evolutionary history of AGT targeting (see the introduction) (30). During vertebrate evolution, the intracellular targeting of AGT has changed on numerous occasions under the influence of dietary selection pressure. Depending on the particular species, AGT can be peroxisomal, peroxisomal and cytosolic, peroxisomal and mitochondrial, mitochondrial, or mitochondrial and cytosolic (25, 30, 39). In general, AGT is more likely to be mitochondrial the more carnivorous the diet, and more peroxisomal the more herbivorous the diet. It appears that the ultimate intracellular destination of AGT depends mainly on whether an N-terminal MTS is either included within, or excluded from, the open reading frame. The apparent hierarchical dominance of the MTS over the PTS1 would lead to low evolutionary conservation pressure on the PTS1 when the MTS is present and may thus have led to the diversity of PTS1 tripeptides observed in mammals. Early mammalian lineages were probably mainly carnivorous or omnivorous with AGT being entirely or mainly mitochondrial (30). Efficient peroxisomal targeting could have evolved on many different occasions as an adaptive response to episodic pressure for more herbivorous diets.

The presence of the PTS1A in rodents, even though it would appear to be unnecessary, suggests that it evolved for some other reason unrelated to peroxisomal targeting. Although the crystal structure of AGT would suggest that this other function...
is unlikely to be related to catalytic activity, it could be involved with the stability of the enzyme. Its ability to enable otherwise inadequate PTS1s, such as KKL in human AGT, SQL in rabbit AGT, and NKL in cat AGT, to function as PTS1s might have been a chance side-effect. If the PTS1s of mammalian AGT evolved on numerous occasions, then because they evolved in the presence of the PTS1A, they did not need to evolve sufficiency. The sufficiency of rodent AGT PTS1s (i.e. those of rat/mouse and guinea pig) might simply result from a purely chance event occurring in their early evolutionary history. Alternatively, the ancestral rodent might have transiently lost its PTS1A, and only re-acquired it after the rodent PTS1 had evolved.

**PTS1A and Kidney Stone Disease**—The efficiency with which AGT is targeted to peroxisomes could be a significant determinant of an individual’s susceptibility to idiopathic calcium oxalate kidney stone disease. This is suggested by the fact that a third of patients with primary hyperoxaluria type 1 have disease, because AGT is redirected away from the peroxisomes toward the mitochondria (1). In addition, some patients with peroxisome biogenesis disorders, such as Zellweger syndrome, in which AGT becomes stuck in the cytosol, have marked hyperoxaluria (40, 41). If the PTS1A, in addition to the PTS1, is a determinant of AGT peroxisomal import efficiency, then naturally occurring amino acid replacements in this region might be expected to affect this efficiency. The knock-off effect of this would be altered levels of oxalate synthesis, which could easily influence the likelihood of calcium oxalate deposition in the kidney. In this context, it is interesting to note that of the three non-synonymous polymorphisms found in human AGT (i.e. Pro → Leu, Val → Ile, and Ile → Met) (42), two are located in the 22-residue PTS1A. Ile → Met segregates with the minor AGXT allele, which also contains Pro → Leu. Val → Ile segregates with a variant called the minor (African) AGXT allele (43). Although the functional effects of the two PTS1A polymorphisms have not been well characterized, it is known that Ile → Met can partially counteract the unfavorable effects of the Pro → Leu polymorphism, which include partial mistargeting, slowing down dimerization, and decreasing specific catalytic activity (3, 44). In some of the mammals discussed in this report (i.e. guinea pig, cat, dog, and cow) residue 340 is normally methionine rather than isoleucine. Whether this has any specific effect on AGT peroxisomal targeting efficiency and oxalate synthesis in these species has yet to be determined.

**REFERENCES**

1. Danpure, C. J. (2001) in *The Metabolic and Molecular Bases of Inherited Disease* (Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Childs, B., Kinzler, K. W., and Vogelstein, B., eds) pp. 3323–3367, McGraw-Hill, New York.
2. Danpure, C. J., Cooper, P. J., Wise, P. J., and Jennings, P. R. (1989) *J. Cell Biol.* **108**, 1345–1352.
3. Purdue, P. E., Takada, Y., and Danpure, C. J. (1990) *J. Cell Biol.* **111**, 2341–2351.
4. Purdue, P. E., Allop, J., Isaya, G., Rosenberg, L. E., and Danpure, C. J. (1991) *Proc. Natl. Acad. Sci. U. S. A.* **88**, 10900–10904.
5. Leiper, J. M., Oatey, P. B., and Danpure, C. J. (1996) *J. Cell Biol.* **135**, 939–951.
6. Lumb, M. J., Drake, A. F., and Danpure, C. J. (1999) *J. Biol. Chem.* **274**, 20587–20596.
7. Mosley, A., Lamb, M. J., Oatey, P. B., Jennings, P. R., De Zoyza, P. A., Wanders, R. J., Tabak, H. F., and Danpure, C. J. (2000) *Biochem. J.* **352**, 409–418.
8. Takada, Y., Kaneko, N., Esumi, H., Purdue, P. E., and Danpure, C. J. (1990) *Biochem. J.* **265**, 517–520.
9. Gould, S. J., Keller, G. A., Hosken, N., Wilkinson, J., and Subramani, S. (1989) *J. Biol. Chem.* **108**, 1657–1664.
10. Swinkels, B. W., Gould, S. J., and Subramani, S. (1992) *FEBS Lett.* **305**, 133–136.
11. Oatey, P. B., Lamb, M. J., Jennings, P. R., and Danpure, C. J. (1996) *Ann. N. Y. Acad. Sci.* **804**, 652–653.
12. Van Der Leij, I., Franse, M. M., Elgersma, Y., Distel, B., and Tabak, H. F. (1995) *Proc. Natl. Acad. Sci. U. S. A.* **90**, 11782–11786.
13. Grocock, F., Kragler, F., Simon, M. M., Schuster, T., and Hartig, A. (1994) *Biochem. Biophys. Res. Commun.* **204**, 1016–1022.
14. Gatto, G., Geisebrecht, B. V., Gould, S. J., and Berg, J. M. (2000) *Nat. Struct. Biol.* **7**, 1091–1095.
15. Lametschwandtner, G., Brocard, C., Fransen, M., Van Veldhoven, P., Berger, J., and Hartig, A. (1996) *J. Biol. Chem.* **271**, 33653–33643.
16. Neuberger, G., Maurer-Stroh, S., Eisenhaber, B., Hartig, A., and Eisenhaber,
Peroxisomal Targeting of Alanine:glyoxylate Aminotransferase

F. (2003) J. Mol. Biol. 328, 567–579
18. Neuberger, G., Maurer-Stroh, S., Eisenhaber, B., Hartig, A., and Eisenhaber, F. (2003) J. Mol. Biol. 328, 581–592
19. Gatto, G. J., Jr., Maynard, E. L., Guerrerio, A. L., Geisbrecht, B. V., Gould, S. J., and Berg, J. M. (2003) Biochemistry 42, 1660–1666
20. Purdue, P. E., Lumb, M. J., and Danpure, C. J. (1992) Eur. J. Biochem. 207, 757–766
21. Birks, G. M., and Danpure, C. J. (1998) Biochem. J. 331, 49–60
22. Oda, T., Miyajima, H., Suzuki, Y., and Ichiyama, A. (1987) Eur. J. Biochem. 168, 537–542
23. Li, X. M., Salido, E. C., and Shapiro, L. J. (1999) Somat. Cell Mol. Genet. 25, 67–77
24. Lumb, M. J., Purdue, P. E., and Danpure, C. J. (1994) Eur. J. Biochem. 221, 53–62
25. Birdsey, G. M., Lewin, J., Cunningham, A., Bru Ford, M. W., and Danpure, C. J. (2004) Mol. Biol. Evol. 21, 632–646
26. Danpure, C. J., Fryer, P., Jennings, P. R., Allsop, J., Griffiths, S., and Cunningham, A. (1994) Eur. J. Cell Biol. 64, 295–313
27. Danpure, C. J., Guttridge, K. M., Fryer, P., Jennings, P. R., Allsop, J., and Purdue, P. E. (1996) J. Cell Sci. 97, 669–678
28. Holbrook, J. D., and Danpure, C. J. (2002) J. Biol. Chem. 277, 2336–2344
29. Holbrook, J. D., Birdsey, G. M., Yang, Z., Bru Ford, M. W., and Danpure, C. J. (2000) Mol. Biol. Evol. 17, 387–400
30. Birdsey, G. M., Lewin, J., Holbrook, J. D., Simpson, V. R., Cunningham, A. A., and Danpure, C. J. (2005) Proc. R. Soc. Lond. B. 272, 833–840
31. Elgersma, Y., Vos, A., Van Den Berg, M., van Roermund, C. W., van der Stuijs, P., Distel, B., and Takah, H. F. (1996) J. Biol. Chem. 271, 26375–26382
32. Maynard, E. L., Gatto, G. J., Jr., and Berg, J. M. (2004) Proteins 55, 856–861
33. Mizuno, T., Ito, K., Uchida, C., Kitagawa, M., Ichiyama, A., Miura, S., Fujita, K., and Oda, T. (2002) Histochem. Cell Biol. 118, 321–328
34. Purdue, P. E., and Lazarow, P. B. (1996) J. Cell Biol. 134, 849–862
35. Miura, S., Kasuya Arai, I., Mori, H., Miyazawa, S., Osumi, T., Hashimoto, T., and Fujiki, Y. (1992) J. Biol. Chem. 267, 14405–14411
36. Zhang, X., Roe, S. M., Hou, Y., Bartlam, M., Rao, Z., Pearl, L. H., and Danpure, C. J. (2003) J. Mol. Biol. 331, 643–652
37. Sambrook, J., and Russell, D. W. (2001) Molecular Cloning: A Laboratory Manual, Third Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
38. Braverman, N., Dott, G., Gould, S. J., and Valle, D. (1998) Hum. Mol. Genet. 7, 1195–1205
39. Caldwell, E. F., Mayor, L. R., Thomas, M. G., and Danpure, C. J. (2004) Hum. Genet. 115, 504–509
40. Wanders, R. J., van Roermund, C. W., Westra, R., Schutgens, R. B., van der Ende, M. A., Tager, J. M., Mannens, L. A., Baadenhuyse, H., Goovaerts, L., Przyrembel, H., Wolff, E. I., Blom, W., Huijmans, J. G., and van Laerhoven, F. G. (1987) Clin. Chim. Acta 165, 311–319
41. Danpure, C. J., Fryer, P., Griffiths, S., Guttridge, K. M., Jennings, P. R., Allsop, J., Moser, A. B., Moser, H. W., MacCollin, M., and DeVivo, D. C. (1994) J. Inher. Metab. Dis. 17, 27–40
42. Coulter-Mackie, M. B., and Rumsby, G. (2004) Mol. Genet. Metab. 83, 38–46
43. Coulter-Mackie, M. B., Tung, A., Henderson, H. E., Toone, J. R., and Applegarth, D. A. (2003) Mol. Genet. Metab 78, 44–50
44. Lumb, M. J., and Danpure, C. J. (2000) J. Biol. Chem. 275, 36415–36422

Downloaded from http://www.jbc.org/ at Murdoch University (CAUL) on May 5, 2019
Peroxisomal Import of Human Alanine:glyoxylate Aminotransferase Requires Ancillary Targeting Information Remote from Its C Terminus
Pia A. J. Huber, Graeme M. Birdsey, Michael J. Lumb, David T. R. Prowse, Tommy J. Perkins, Daniel R. Knight and Christopher J. Danpure

J. Biol. Chem. 2005, 280:27111-27120.
doi: 10.1074/jbc.M502719200 originally published online May 23, 2005

Access the most updated version of this article at doi: 10.1074/jbc.M502719200

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2005/05/24/M502719200.DC1

This article cites 40 references, 16 of which can be accessed free at
http://www.jbc.org/content/280/29/27111.full.html#ref-list-1